{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Phase III Trials Redefine Optimal Therapy in Gastroenterological Cancers - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"TvGKMtbBy5\"><a href=\"https:\/\/themedicalxchange.com\/en\/2011\/06\/03\/2011-american-society-of-clinical-oncology-asco-an\/\">Phase III Trials Redefine Optimal Therapy in Gastroenterological Cancers<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2011\/06\/03\/2011-american-society-of-clinical-oncology-asco-an\/embed\/#?secret=TvGKMtbBy5\" width=\"600\" height=\"338\" title=\"&#8220;Phase III Trials Redefine Optimal Therapy in Gastroenterological Cancers&#8221; &#8212; The Medical Xchange\" data-secret=\"TvGKMtbBy5\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2011\/06\/ASCO_Figure_1.JPG","thumbnail_width":960,"thumbnail_height":720,"description":"Chicago \u2013 Several large trials, including late breakers, presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting have helped refine current standards for the treatment of cancers in the gastrointestinal (GI) tract. It is noteworthy that several agents resurfaced in effective regimens across different sites along the GI tract. According to the new data, targeted therapies, such as monoclonal antibodies (mABs) and tyrosine kinase inhibitors (TKIs) do appear to have a role in selected populations, but the new data are more remarkable for their support of cytotoxic agents. Overall, the innovations in treatment appear more likely to build on the advantages of current standard regimens, such as FOLFOX (leucovorin, 5-fluorouracil, and oxaliplatin) in colon cancer, than to replace these strategies. Two of the most important studies in regard to understanding the current direction of state-of-the-art therapy were conducted in the adjuvant setting for colon cancer, but preoperative therapy in rectal cancer was another area in which there are significant new data."}